Literature DB >> 23576133

Improvement of quality of life in patients with chronic inflammatory demyelinating polyneuropathy shifting from 16 to 20% subcutaneous immunoglobulins.

Dario Cocito1, Ilaria Paolasso, Erdita Peci, Emanuela Spagone, Leonardo Lopiano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23576133     DOI： 10.1007/s10072-013-1426-5

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  5 in total

1.  European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision.

Authors:  P Y K Van den Bergh; R D M Hadden; P Bouche; D R Cornblath; A Hahn; I Illa; C L Koski; J-M Léger; E Nobile-Orazio; J Pollard; C Sommer; P A van Doorn; I N van Schaik
Journal:  Eur J Neurol       Date:  2010-03       Impact factor: 6.089

2.  Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies.

Authors:  Hubertus Köller; Michael Schroeter; Heinrich Feischen; Hans-Peter Hartung; Bernd C Kieseier
Journal:  J Neurol       Date:  2006-08-11       Impact factor: 4.849

3.  Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy.

Authors:  De-Hyung Lee; Ralf A Linker; Walter Paulus; Christiane Schneider-Gold; Andrew Chan; Ralf Gold
Journal:  Muscle Nerve       Date:  2008-03       Impact factor: 3.217

4.  The efficacy of subcutaneous immunoglobulin administration in chronic inflammatory demyelinating polyneuropathy responders to intravenous immunoglobulin.

Authors:  Dario Cocito; Grazia Serra; Yolanda Falcone; Ilaria Paolasso
Journal:  J Peripher Nerv Syst       Date:  2011-06       Impact factor: 3.494

5.  A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study.

Authors:  Siraj A Misbah; Andreas Baumann; Raffaella Fazio; Patrizia Dacci; Dirk S Schmidt; Janet Burton; Matthias Sturzenegger
Journal:  J Peripher Nerv Syst       Date:  2011-06       Impact factor: 3.494
  5 in total
  3 in total

Review 1.  Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies.

Authors:  Verena I Leussink; Hans-Peter Hartung; Bernd C Kieseier; Mark Stettner
Journal:  Ther Adv Neurol Disord       Date:  2016-04-06       Impact factor: 6.570

2.  Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study.

Authors:  Ivo N van Schaik; Orell Mielke; Vera Bril; Nan van Geloven; Hans-Peter Hartung; Richard A Lewis; Gen Sobue; John-Philip Lawo; Michaela Praus; Billie L Durn; David R Cornblath; Ingemar S J Merkies
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-07-03

3.  Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.

Authors:  Ivo N van Schaik; Nan van Geloven; Vera Bril; Hans-Peter Hartung; Richard A Lewis; Gen Sobue; John-Philip Lawo; Orell Mielke; David R Cornblath; Ingemar S J Merkies
Journal:  Trials       Date:  2016-07-25       Impact factor: 2.279
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.